GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 80.96B |
| Revenue (ttm) | 32.67B |
| Net Income (ttm) | 5.72B |
| Shares Out | 3.99B |
| EPS (ttm) | 1.39 |
| PE Ratio | 14.61 |
| Forward PE | 11.25 |
| Dividend | 0.72 (3.57%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 10,394,027 |
| Average Volume | 6,265,989 |
| Open | 1,964.50 |
| Previous Close | 2,016.00 |
| Day's Range | 1,964.50 - 2,038.00 |
| 52-Week Range | 1,288.61 - 2,282.00 |
| Beta | 0.35 |
| RSI | 40.71 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
GSK to Report Q1 Earnings with Strong Revenue Expectations
GSK to Report Q1 Earnings with Strong Revenue Expectations
GSK Receives FDA Priority Review for Bepirovirsen in Chronic Hepatitis B Treatment
GSK Receives FDA Priority Review for Bepirovirsen in Chronic Hepatitis B Treatment
FDA Accepts Priority Review And Grants BT Designation For Bepirovirsen In Chronic Hepatitis B
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) partner GSK on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for Bep...
GSK Receives Fast-Track Review for New Hepatitis B Treatment
GSK Receives Fast-Track Review for New Hepatitis B Treatment
GSK Secures Breakthrough Therapy Designation for Efimosfermin
GSK Secures Breakthrough Therapy Designation for Efimosfermin
GSK Faces Court Ruling Favoring TESARO in Dispute
GSK Faces Court Ruling Favoring TESARO in Dispute
GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute
GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduction Trial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Te...
Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest
The FTSE 100 Index pulled back this week as the US-Iran war continued and after the UK published a hot consumer inflation report. It dropped to £10,365 from this month's high of £10,687.
Mandelson’s lobbying firm Global Counsel went bust owing £4.6m, report says
HMRC owed more than £640,00 by company that advised clients such as TikTok, GSK and Palantir Peter Mandelson’s former consultancy business, Global Counsel, went bust owing £4.6m – including more than ...
FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings
The FTSE 100 Index pulled back for three consecutive days as companies exposed to the ongoing US-Iran war slipped and as the UK published a strong inflation report. It also dropped as market particip...
GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment
GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment
GSK Reports Promising Phase I Results for Novel Cancer Treatment
GSK Reports Promising Phase I Results for Novel Cancer Treatment
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer
Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in th...
GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50%
GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50%
GSK Reports Promising Early Data For Experimental Cancer Drug
British drugmaker GSK plc (NYSE: GSK) is betting on blockbuster potential for its experimental cancer therapy Mo-rez, after early trial data showed the drug shrank tumors in patients with advanced, h...
GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer
(RTTNews) - GSK plc (GSK, GSK.L) announced encouraging findings from its global phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez), a novel antibody-drug conjugate (ADC) targeting the B...
GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug
GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug
GSK reports promising early results in ovarian and womb cancer drug trial
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug GSK has revealed positive results for a treatment for gynaecological cancers as its chief executiv...
GSK sees blockbuster potential in targeted cancer therapy after promising early data
British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in ...
GSK Withdraws Approval for Wellcovorin Drug Amid Market Changes
GSK Withdraws Approval for Wellcovorin Drug Amid Market Changes
GSK (GSK) Withdraws Leucovorin Calcium Application from FDA
GSK (GSK) Withdraws Leucovorin Calcium Application from FDA
GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.
Generic versions of the drug will still be available to treat a rare genetic condition.
GSK (GSK) Gains Approval for Exdensur in China, Stock Rises
GSK (GSK) Gains Approval for Exdensur in China, Stock Rises